I obtained a Degree in Chemistry (Univ. Ramon Llull, 1994) and Chemical Engineering (IQS, 1995). After obtaining a Ph D in Organic Chemistry (University of Barcelona, 1999) I joined the group of Lewis Kay in Toronto for a post-doctoral stay (University of Toronto, 2000-2004). I was then recipient of a Ramon y Cajal reincorporation contract at the Parc Científic de Barcelona (2004-2006) and I currently am a group leader at the Structural Biology Unit of the CIC bioGUNE. My research line focuses on the use of nuclear magnetic resonance (NMR) to the study of biologically relevant proteins and enzymes, paying special attention to the delicate balance existing between protein stability and dynamics. Such knowledge is applied for the development of new compounds with therapeutic activity in the field of rare diseases, and it has developed into the creation of a spin-off company, ATLAS Molecular Pharma. I have found a new pharmacological chaperone for the treatment of congenital erythropoietic porphyria, which is a repurposed drug and it has obtained the Orphan Drug Designation status. Additionally, I am also interested in the NMR-based metabolomics of biofluids for the diagnose of rare and prevalent diseases. I have been awarded the prize of the Real Sociedad Española de Química (2004), the Spanish NMR group prize (2005), the Elhuyar-Goldshmidt Prize (2022) and nominated Academic of the Academy of Medical Sciences of the Basque Country (2016). I am currently the president of the Spanish Chemical Biology group.
Perfil del socio/a
Óscar Millet
Comisión de admisiones: Vocal (2024-2028)